Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer

NCT01251874 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01251874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01251874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 22, 2010
Completion date
November 19, 2026
Enrollment
44 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent breast carcinoma, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, triple-negative breast carcinoma